Moderna withdrew its application for FDA approval of its mRNA-1083 combination vaccine (flu + COVID-19) on May 21, citing plans to resubmit after Phase 3 data for its standalone mRNA-1010 flu vaccine becomes available later in 2024. The withdrawal follows stricter FDA demands for new clinical trial…